Page last updated: 2024-11-05

thalidomide and Mycoplasma dispar Infection

thalidomide has been researched along with Mycoplasma dispar Infection in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

ExcerptRelevanceReference
"Recognition and timely adequate treatment of erythema multiforme remain a major challenge."2.58Current Perspectives on Erythema Multiforme. ( Harr, T; Lerch, M; Mainetti, C; Terziroli Beretta-Piccoli, B, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lerch, M1
Mainetti, C1
Terziroli Beretta-Piccoli, B1
Harr, T1

Reviews

1 review available for thalidomide and Mycoplasma dispar Infection

ArticleYear
Current Perspectives on Erythema Multiforme.
    Clinical reviews in allergy & immunology, 2018, Volume: 54, Issue:1

    Topics: Acyclovir; Dapsone; Drug-Related Side Effects and Adverse Reactions; Erythema Multiforme; Herpes Sim

2018